Meningococcal B vaccination (Bexsero) to help prevent Meningococcal disease in NZ
Speaker
Session Date:
NZ has one of the highest rates of meningococcal disease in the world.
A funded meningococcal B vaccine (Bexsero) has the potential to reduce the incidence of meningococcal disease in NZ.
Kim will cover meningococcal disease in NZ, the impact of meningitis B vaccination programmes overseas, as well as information and practical considerations for the incorporation of Bexsero on the Immunisation Schedule and the funded catch-up programme.
With sponsorship from:
in partnership with
